Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733238 · ClinicalTrials.gov registry record · Phase 2
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01733238 is a Phase 2 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 13 participants.
The verdict
NCT01733238, a Phase 2 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733238
The ClinicalTrials.gov registry entry for NCT01733238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT01733238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733238 about?
NCT01733238 is a clinical study titled "Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
What is the current status of trial NCT01733238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01733238?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT01733238?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.